0:000:00
<p>The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I The KETO-CTA Study</strong></p> <ul> <li><strong>JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686</strong></li> <li><strong>Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009</strong></li> </ul> <p><strong>II Subclinical AF – Anticoagulate or Not?</strong></p> <p><strong>Anticoagulation in Subclinical AF May Offer Little Benefit</strong></p> <p> <strong>https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31</strong></p> <p><strong>Treat AFib 'Diagnosed' by Smartwatch</strong></p> <p> https://www.medscape.com/viewarticle/treat-af...